Early glycemic control and subsequent risk of incident dementia among new metformin users
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Achieving glycated hemoglobin (HbA1c) below 7% in type 2 diabetes patients starting metformin is linked to reduced dementia risk. Tighter glycemic control below 6.5% showed no additional dementia prevention benefits.
Area Of Science
- Endocrinology
- Neurology
- Public Health
Background
- Individuals with diabetes face a higher risk of developing dementia.
- Optimal blood sugar control targets for preventing dementia in patients initiating metformin monotherapy remain unclear.
Purpose Of The Study
- To investigate the relationship between early glycemic control and dementia risk in individuals starting metformin monotherapy.
- To determine optimal hemoglobin A1c (HbA1c) targets for dementia risk reduction.
Main Methods
- Utilized Danish health registry data from 2000-2018, analyzing metformin monotherapy initiators aged 50+.
- Employed standard hazard and propensity-score based models to assess the association between early glycemic control and incident dementia.
- Explored subgroup effects based on age, calendar year, and cardiovascular disease status.
Main Results
- Among 46,332 patients, 83% achieved HbA1c <7% within one year. Elevated dementia risk was observed with HbA1c levels >7%.
- Little difference in dementia risk was found between achieving HbA1c <7% and tighter controls (e.g., <6.5% or <6%).
- Benefits of glycemic control on dementia risk appeared limited to those without cardiovascular disease and manifested over several years.
Conclusions
- Supports current recommendations for early glycemic control (HbA1c <7%) in type 2 diabetes for dementia risk reduction.
- Provides evidence that pursuing very tight glycemic control (HbA1c <6.5% or <6%) offers no additional dementia prevention benefits.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...